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Abstract
The surrogate light chain (SL) is composed of two polypeptides, Vpre-B and λ5. In large pre-BII cells
the SL chain associates with Ig m heavy chain (mH) to form the pre-B cell receptor (pre-BCR). In
mice there are two Vpre-B genes which are 98% identical within the coding regions. The two genes
are co-expressed at the RNA level and encode functional proteins that can assemble with λ5.
However, it is not known whether both gene products serve the same function in vivo. Here we
have established mice that lack the Vpre-B1 gene (VpreB1–/–), but still express the Vpre-B2 gene, both
as RNA and protein. In Vpre-B1–/– mice, the bone marrow cellularity and the percentage of B220F
cells is normal. However, among the B220F cells, the percentage of pre-BI cells is increased, and
the percentage of pre-BII and immature B cells is slightly decreased, suggesting that the lack of
Vpre-B1 causes a partial block at the transition from pre-BI to pre-BII cells, i.e. into the pre-BCR
stage. The number of cells that produce a functional pre-BCR is thus lower, but the cells that reach
this stage are normal as they can be expanded by proliferation and then differentiate into more
mature cells. The spleens of Vpre-B1 homozygous mutant mice show normal numbers of B and T
lymphocytes. Moreover, the Ig loci are allelicly excluded and the homozygous mutant mice respond
with normal levels of antigen-specific antibodies to T-dependent antigens. These results
demonstrate that Vpre-B2 alone is capable of supporting B lymphocyte development in the bone
marrow and can give rise to immuno-competent cells in the periphery.
Introduction
The λ5 and Vpre-B genes are expressed early in B lymphocyte
development, i.e. in pro-B/pre-BI and large pre-BII cells (1–
6). Together they encode the surrogate light chain (SL) chain,
which has distinct homologies to conventional Ig chains (7).
In pro-/pre-BI cells the SL chain associates with a complex
of glycoproteins; however, its function at this stage of develop-
ment is not yet clear (8). In the large pre-BII cell stage the
SL chain associates with the Ig µ heavy (µH) chain and forms
the pre-B cell receptor (pre-BCR) (9,10). Experiments in which
either the transmembrane part of µH or the λ5 gene has been
disrupted show that the pre-BCR affects the expansion of large
pre-BII cells into more mature B cell compartments (11,12).
In mice, the λ5 chain is encoded by a single gene, whereas
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the Vpre-B chain is encoded by two genes (3,13). The two
Vpre-B genes are almost identical; only 9 bp difference in the
coding regions causing a difference of 4 amino acids between
the two polypeptides (3,7). On the mRNA level, expression
of the Vpre-B1 gene has been detected in all pre-BI and pre-
BII bone marrow cells, while Vpre-B2 was only found in some
of the same pre-BI and pre-BII cells. This, however, might be
due to a difference in detection levels (6). Both genes encode
functional proteins that can assemble with λ5 when expressed
in COS cells (6). Due to the high degree of homology it is not
known if both Vpre-B proteins are present in pre-BI and pre-
BII cells. In this study we analyze how the lack of a functional
Vpre-B1 gene affects B lymphocyte development.
454 Vpre-B1-deficient mice
Fig. 1. Homologous recombination of the Vpre-B1 loci. (A) Configuration
of the Vpre-B1/λ5 genomic locus before (top) and after (bottom)
homologous recombination with the targeting vector (middle).
Homologous integration was detected using EcoRI-digested DNA
and a probe positioned 39 outside the vector. The targeted locus
would give rise to a band of 7.2 kb in size instead of the 9.6 kb non-
targeted allele. Restriction enzyme sites: K, KpnI; M, MboI; X, XbaI;
R, EcoRI; Pv, PvuII; ‘Pv’, destroyed PvuII site; Ps, PstI; B, BamHI. (B)
Southern blot to distinguish the targeted locus. The genomic DNAs
were digested with EcoRI. Lanes 1–8; the E14 embryonic stem cell
line, the positive Y2 clone, mouse #129 (1/1), mouse #128 (1/–),
mouse #127 (–/–), mouse #120 (1/1), mouse #119 (1/–), mouse
#118 (–/–). Mice #127–129 are littermates as are #118–120.
Methods
DNA constructs
All DNA constructs were made using conventional DNA
techniques (14). The Vpre-B1 targeting construct was made in
several steps using subcloned fragments from the phage
7pB12 (13). The final construct contained the following in 59
to 39 order (Fig. 1): a 3.2 kb XbaI–PvuII fragment from the
region 59 of exon I was followed by the neo gene from
pMC1neopolyA. Downstream of neo is an additional 46 bp
(from PvuII to PstI) also located in the 59 untranslated region
of Vpre-B1. The rest of exon I and most of exon II were removed
by deleting the fragment between this PstI site and the PstI
site within exon II. The C-terminal 109 bp of exon II is present,
as well as the 2.1 kb of 39 sequence up to the XbaI site. This
construct therefore contains the sequence for 36 out of 142
amino acids encoded by the Vpre-B1 gene. The thymidine
kinase gene was inserted downstream of the Vpre-B1 sequence
(but was not taken advantage of).
Embryonic stem cells and transfections
The procedure has been described before (12). Briefly, the
embryonic stem cell line E14 was grown in Iscove’s medium
supplemented with 2-mercaptoethanol, MEM, antibiotics, LIF
(0.1%) and 15% FSC (Boehringer). The LIF was harvested
from CHO-LIF cells. Tissue culture plates were gelatinized
with 0.1% gelatine after which a layer of G418-resistant
embryonic fibroblasts was plated. The fibroblasts were irradi-
ated with 3000 rad before adding the embryonic stem cells.
The embryonic stem cells were used at 107 cells per transfec-
tion event. The cells were transfected by electroporation and
after ~36 h selected in 0.2 mg (active) G418/ml. Resistant
colonies were picked, expanded and frozen. Parallel cultures,
in the absence of feeder cells, were set up for preparation of
genomic DNA.
Screening of positive embryonic stem cell clones
Genomic DNA from individual clones were screened by
Southern blotting. The DNA was digested with KpnI. The
probe used was derived from a region outside the construct.
Positive colonies were confirmed by digestion with EcoRI
using a probe not contained in the targeting construct (Fig.
1; probe, 1.9 kb BamHI–KpnI fragment). Clone Y2, which was
later used to establish mice, was further confirmed by several
other restriction enzyme digests.
Mice
The Y2 clone was used to establish chimeric mice, using
blastocysts from C57Bl/6. The male chimeras were bred with
C57Bl/6 females, and heterozygous and homozygous mice
were established. After this the mice were interbred. The
C57Bl/6 mice were obtained from Bomholtgaard (Ry,
Denmark).
Screening tail DNA for genotype
Tail DNA was prepared as described (12). To distinguish
between wild-type, heterozygous and homozygous mice we
used Southern blotting as described above or a PCR assay
in which a mixture of 3 primers (VpB1 sense, VpB1 antisense
and neo sense) were used. The thermal cycling profile was:
94°C, 20 s; 62°C, 20 s; 72°C, 30 s for 30 cycles. Under these
conditions the wild-type allele gives rise to a 430 bp fragment
and the disrupted allele yields a 230 bp fragment.
Oligonucleotides
The oligonucleotides used were as follows. neo sense: 59-
AAGGCACCTTGGAGGTAATGCAT-39. HGPRT sense: GCTG-
GTGAAAAGGACCTCT. HGPRT anti-sense: 59-CACAGGACT-
AGAACACCTGC. The Vpre-B1, Vpre-B2 and λ5 primers have
been described before (6).
RNA isolation and RT-PCR
Total RNA from bone marrow cells was isolated using
Ultraspec and conditions according to the manufacturer
(Ultraspec; Biotec). First-strand cDNAs were synthesized from
1 µg total RNA by reverse transcription with random primers
and these cDNAs were used as templates in PCR reactions
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Fig. 2. Lack of Vpre-B1 expression in bone marrow cells of Vpre-B1–/–
mice. Bone marrow cells from the mice in Fig. 1 were used for RNA
preparations. An RT-PCR assay, that distinguishes Vpre-B1 from Vpre-B2
message, was used to analyze for Vpre-B gene expression (6).
The lower band represents RNA (cDNA) while the upper band
corresponds to genomic DNA (87 bp larger). The presence of λ5
message was also tested. HGPRT was used as a control for the
amount and quality of the cDNA. Lanes 1, 5, 9 and 13: negative
control (–); lanes 2, 6, 10 and 14: mouse #118 (–/–); lanes 3, 7, 11
and 15: mouse #119 (1/–); lanes 4, 8, 12 and 16: mouse #120 (1/1).
Fig. 3. In vitro cultured pre-B cells express Vpre-B2 on the cell surface.
Total bone marrow from heterozygous and homozygous 7-week-old
littermates were cultured on ST2 cells in the presence of IL-7 (15).
After 6 days cells were stained with antibodies recognizing CD45R
and Vpre-B (VP245) or an isotype-matched control antibody (rat IgG2a)
and analyzed by FACS. In the lymphocyte gate 99% of the cells
expressed the CD45R marker. The data are presented as a histogram
showing cell number and fluorescence intensities of the isotype
control (dashed line) and VP245 (solid line) antibody stainings.
(14) using a DNA thermal cycler (Perkin-Elmer, Foster City,
CA) with Taq polymerase from Gibco/BRL (Bethesda, MD).
Differential amplification of specific Vpre-B1 and Vpre-B2 tran-
scripts was performed as described (6). Samples were also
assayed for level of HGPRT transcripts, as a control for the
quality and quantity of RNA. Also λ5 message was analyzed
to confirm that it was not affected by the Vpre-B1 deletion or
by the insertion of the neo-resistance gene. The λ5 message
was detected as described before (6).
Pre-B cell cultures
Pre-B cells from bone marrow of the indicated mice (Fig. 3)
were cultured for 6–7 days as described (15). Briefly, ~25–
503103 total bone marrow cells were plated in 24-well plates
on γ-irradiated ST2 stromal cells in the presence of 100 U IL-
7/ml (16). The cells were cultured in IMDM-supplemented with
2-mercaptoethanol, antibiotics and 5% heat-inactivated FCS.
Flow cytometric analysis
Single-cell suspensions from bone marrow were prepared by
flushing out cells from femurs with ice-cold staining buffer
(HBSS containing 3% FCS). Spleen, lymph node and thymus
cells in single-cell suspensions were stained with the anti-
bodies described below and then analyzed by flow cytometry
(FACS) using a FACSort (Becton Dickinson). The cells were
gated on the extended lymphocyte gate and then analyzed
for reactivity with mAb as described (17,18). Antibodies
recognizing the following markers were used: CD45R (B220,
FITC-conjugated from PharMingen), CD43, CD25 and IgM
(biotinylated from PharMingen), c-kit (19) and Vpre-B (VP245)
(8) (the latter antibodies were biotinylated by us), CD4 [phyco-
erythrin (PE)-conjugated from PharMingen], CD4 (GK1.5,
FITC-conjugated by us), CD5 (biotinylated from PharMingen),
CD8 (PE-conjugated from PharMingen), CD19 (biotinylated
from PharMingen) and IgD (1.19, biotinylated by us). Biotinyl-
ated antibodies were revealed by PE–streptavidin (Southern
Biotechnology Associates, Birmingham, AL). For the Ig allelic
exclusion analysis antibodies recognizing IgMa (RS3.1, FITC-
conjugated by us) and IgMb (PE-conjugated from Phar-
Mingen) allotypes were used.
Immunizations and ELISA
Wild-type, heterozygous and homozygous mice (four to five
mice in each group) were immunized i.p. with 100 µg of the
T-dependent antigen phenyl-oxazolone coupled to ovalbumin
as alum precipitate. Two weeks later sera were collected and
analyzed for the presence of hapten-specific (plates coated
with phenyl-oxazolone coupled to BSA) or carrier-specific
(ovalbumin) antibodies in ELISA.
Results
Establishment of Vpre-B1-deficient mice
To analyze the role of Vpre-B1 and Vpre-B2 in B cell development
we set out to establish mice lacking the germline Vpre-B1 gene.
Comparing the restriction enzyme maps of the two Vpre-B
genes shows that the homology between the two extends no
further than a few hundred base pairs 59 and 39 of the coding
regions (6). Therefore, a vector that would disrupt the Vpre-B1
gene would not be expected to integrate at the Vpre-B2 locus
at this frequency. A vector to replace the Vpre-B1 gene with
the gene encoding neomycin resistance was constructed as
shown in Fig. 1(A). Embryonic stem cells were transfected
and G418-resistant clones screened for homologous recomb-
ination. One clone, Y2, out of 352 analyzed was found to
carry a disrupted Vpre-B1 gene on one allele and was therefore
used to establish mice homozygous for the deletion in the
Vpre-B1 gene (VpB1–/–). A Southern blot is shown in Fig. 1(B)
in which EcoRI-digested DNA from several sources was
analyzed by hybridization with the 1.9 kb probe in Fig. 1(A).
The E14 embryonic stem cell line shows one band of ~9.6
kb, while the Y2 clone shows two bands, one of which is 9.6
kb and the other is 7.2 kb. The latter band corresponds to
the disrupted Vpre-B1 allele. In the same figure is shown DNA
from individual mice, some of which are wild-type (1/1),
heterozygous (1/–) and homozygous (–/–). Thus, the Y2
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embryonic stem cell clone gave rise to mice with a deletion
in the Vpre-B1 gene.
Presence of Vpre-B2 but not Vpre-B1 RNA
To confirm that the mutation abolished expression of Vpre-B1
transcripts, bone marrow RNA was prepared from the mice
analyzed in Fig. 1. The RNAs were analyzed in a RT-PCR-
based assay which distinguishes between Vpre-B1 and Vpre-
B2 mRNA (6). As seen in Fig. 2, Vpre-B1 wild-type (1/1),
heterozygous (1/–) and homozygous mutant (–/–) mice all
made Vpre-B2 mRNA. However, Vpre-B1 transcripts could not
be detected in Vpre-B1–/– mice, while they were found in both
the wild-type and heterozygous mutant mice, as expected.
PCR of Vpre-B1 or Vpre-B2 produced two bands, the larger of
which corresponds to either genomic DNA or unspliced RNA
(the primers span the 87 bp intron). Note that Vpre-B1–/– mice
also lacked this band when Vpre-B1, but not Vpre-B2 expression
was examined (cf. Fig. 2, lanes 10 and 14). Since the Vpre-B1
sense primer is situated in the region that was deleted upon
homologous recombination, this provided additional evidence
that this part of the Vpre-B1 gene had been deleted. The same
cDNA preparations were also analyzed for the presence of
λ5 (and HGPRT) message and similar levels were detected
in all mice. This demonstrates that expression of the λ5 gene
was not affected by the Vpre-B1 deletion or by the insertion of
the neo resistance gene into the Vpre-B1 locus which is located
4–5 kb upstream of the λ5 gene. Thus, the targeting vector
disrupted the Vpre-B1 gene and prevented its expression but
did not alter expression of λ5 or Vpre-B2.
The Vpre-B2 gene encodes a functional protein
Earlier experiments showed that both Vpre-B1 and Vpre-B2 could
associate with λ5 to form a SL chain (6). Since the Vpre-B2,
but not the Vpre-B1, gene was expressed in the mutant mice
we investigated if Vpre-B2 was present on the cell surface of
bone marrow-derived pre-B cells cultured in vitro (15). After
6 days in culture on stromal cells, in the presence of IL-7, the
cells were analyzed by FACS after staining for expression of
B220 (CD45R) versus an antibody (VP245) that recognizes
both the Vpre-B1 and Vpre-B2 proteins or an isotype-matched
control antibody (6,8). The cells in the lymphocyte gate were
large and 99% stained positive for B220 (data not shown).
Figure 3 shows that the VP245 antibody recognized a cell
surface bound Vpre-B protein in cells from both Vpre-B1 hetero-
zygous and homozygous mutant mice which, in the latter
case, corresponds to only Vpre-B2. Thus, as suggested earlier
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Fig. 4. Partial block in B cell development at the transition into the pre-BCR stage. (A) Expression of CD45R versus IgM, CD25 (IL2-Rα), CD43
and CD117 (c-kit) respectively on bone marrow cells from Vpre-B1 heterozygous (1/–) and homozygous (–/–) mutant mice at ~8 weeks of age.
Shown is the staining pattern after gating on lymphoid cells. (B) Expression of CD45R versus IgM. The B220lo/int cells were selected as gate
R2 and the percentage of IgM1 cells within this gate determined; M1. (C) The cells in (A) were analyzed by gate R2 (B220lo/int) to determine
M1. The data are displayed as histograms showing the M1 values, i.e. percentage of cells in gate R2 being positive for IgM, CD25, CD43 or
CD117. (D) Between one and 10 mice per group (in several separate experiments) were analyzed as in (C). The M1 values for IgM, CD43
and CD117 are shown. Student’s t-test on the decrease in percentage of IgM1 cells gave a P , 0.1, i.e. highly significant. The CD117 staining
has been confirmed with more wild-type and homozygous mutant mice using another CD117 antibody. (E) The CD251 cells in (A) were gated
and the percentage of small (FSC) cells determined.
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Fig. 5. Allelic exclusion of the IgH loci. Cells from spleen (left panel) and bone marrow (right panel) were stained with markers specific for
IgMa versus IgMb allotype. Cells from Vpre-B1 homozygous mutant, Ig allotype heterozygous, mice are shown.
(6), the Vpre-B2 gene encodes a functional protein that can be
expressed on the cell surface of pre-B cells.
Partial block at the transition into the pre-BCR stage
To determine whether the failure to express Vpre-B1 had any
effect on B cell development we first analyzed the spleen of
Vpre-B1–/– mice. Here, we found that the total number of cells,
and the percentages of cells expressing B220, IgM, CD8 and
CD4 were about normal, suggesting that the peripheral B
and T cell compartments were not affected (data not shown).
We then analyzed B220 and IgM expressing B cells in lymph
nodes which showed the same pattern in all three genotypes
(data not shown). Lastly, analysis of thymus demonstrated a
normal pattern of CD4 and CD8 positive cells (data not
shown). Thus, spleen, lymph node and thymus in the Vpre-B1-
deficient mice were normal in terms of B and T lymphocytes.
Since SL chain is expressed and functions specifically at
early stages of B cell development, bone marrow cells were
analyzed by different means. The cells were counted and the
number of nucleated cells in homozygous mutant mice was
found to be similar to that of wild-type and heterozygous
mutant mice. Thereafter cells were analyzed for expression
of B220 in combination with either IgM, CD25, CD43 or
CD117 (c-kit). The differential expression of these markers
is characteristic of their differentiation stage (17,18). The
percentage of cells expressing B220 was found to be ~50%
in all three genotypes. As shown in Fig. 4(A), the homozygous
mutant mice stained positive for B220 in combination with all
the above-mentioned markers. However, the percentage of
cells in the various compartments differed in Vpre-B1–/– mice
as compared to heterozygous and wild-type mice: the B2201
c-kit1 and B2201 CD431 compartments were increased,
while the B2201 CD251 and B2201 IgM1 compartments were
slightly decreased.
To more closely analyze these differences, bone marrow
cells that expressed low to intermediate levels of B220
(B220lo/int) were analyzed further (B220high cells are recirculat-
ing cells). The B220lo/int cells were gated (Fig. 4B, gate R2)
and the percentage of cells within this gate that expressed
the above markers determined (Fig. 4B, M1). As shown in
the histograms in Fig. 4(C) and the summary in Fig. 4(D), the
percentage of B220lo/int IgM1 cells was slightly decreased in
Vpre-B1–/– mice. The same result was also observed for B220lo/
int CD251 cells (Fig. 4C and data not shown). In contrast, the
percentage of B220lo/int CD1171 cells was ~2-fold higher in
homozygous as compared to heterozygous mutant mice. This
was also the case for B220lo/int CD431 cells. A summary of
several experiments, which also included wild-type mice, is
shown in Fig. 4(D). Since the number of bone marrow cells
in all three genotypes was about the same, the increase in
the percentage of B220lo/int CD1171 cells represented an
increase in the actual number of B220lo/int CD1171 cells. The
size distribution among the cells that expressed either CD117,
CD43, CD25 or IgM was similar among the three genotypes,
suggesting that the lack of Vpre-B1 did not affect the expression
of these markers per se (Fig. 4E and data not shown). Thus,
the number of bone marrow cells expressing B220lo/int in
combination with CD117 and CD43 was enriched for by a
factor of 2, while B220lo/int CD251 and B220lo/int IgM1 cells
were each decreased by ~20% in Vpre-B1–/– mice.
Pre-BI cells express B220, CD117 and CD43 but not CD25;
pre-BII cells are B2201 CD251 but lack c-kit and CD43. The
CD25 marker is not found on more differentiated cells, i.e.
immature and mature B cells (18). Large pre-BII cells that
express a functional pre-BCR are expanded by proliferation
and, upon differentiation, give rise to small pre-BII cells.
Among the B220lo/int CD251 cells ~20 and 80% constituted
large and small cells respectively in all three genotypes (Fig.
4E and data not shown). This suggested that cells with a
functional pre-BCR were expanded also in the marrow of
Vpre-B1 homozygous mutant mice. Thus, bone marrow from
Vpre-B1–/– mice exhibited an enrichment in pre-BI cells (B220lo/
int CD1171 CD431) and a reduction in large pre-BII cells
(B220lo/int CD251) suggesting that the lack of Vpre-B1 affected
B lymphocyte development at the transition into the pre-
BCR stage.
Ig allelic exclusion in VpreB1-deficient mice
To determine if the Vpre-B2-containing pre-BCR was functional
in terms of allelic exclusion of the Ig loci, we analyzed spleen
and bone marrow cells by FACS for the presence of both Ig
allotypes in Iga/Igb heterozygous mice. As shown in Fig. 5,
.98% of all sIgM1 B cells of bone marrow and of spleen
from VpreB1–/– Ig allotype heterozygous mice expressed either
one or the other, but not both Ig allotypes on one cell. Thus,
a defective Vpre-B1 gene did not affect Ig allelic exclusion.
Normal immune response against T-dependent antigens
We next examined the ability of Vpre-B1-deficient mice to mount
a T-dependent antigen response by immunizing with the
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Fig. 6. Normal immune response to a T-dependent antigen. Vpre-B1
wild-type (1/1), heterozygous (1/–) and homozygous (–/–) mutant
mice were immunized (i.p.) with 100 µg alum precipitate of the T-
dependent antigen phenyl-oxazolone coupled to ovalbumin as a
carrier. Two weeks later sera were taken and analyzed for hapten
(Ox)-specific antibodies in ELISA. Each group contained four or five
mice. Shown is the titer of each serum at 50% of the plateau level.
Sera from non-immunized mice: ,1.
hapten phenyl-oxazolone coupled to the carrier ovalbumin.
Two weeks after immunization, serum were tested in ELISA
for the presence of hapten- and carrier-specific antibodies.
As shown in Fig. 6, all mice showed a good response to the
hapten, independent of the status of the Vpre-B1 loci. The
response to the ovalbumin carrier was also normal in all mice
(data not shown). Therefore, the absence of Vpre-B1 did not
alter the immune response to T-dependent antigens.
Discussion
Our aim here was to evaluate the role in B lymphocyte
development of one of the two Vpre-B genes present in the
mouse genome, i.e. the Vpre-B1 gene. We find that disruption
of the Vpre-B1 gene causes a partial block in B cell development
at the transition into the pre-BCR stage as defined by an
increase in the number of pre-BI cells and a slight decrease
in the number of large pre-BII cells. However, the number of
mature B cells in the periphery was not affected. Moreover,
allelic exclusion of IgH gene expression, in the central and
peripheral B cell compartments, is functional as are T cell-
dependent immune responses. This demonstrates that both
Vpre-B gene products are functional and involved in the
formation of the pre-BCR. It also shows that Vpre-B2 alone is
sufficient, but not as efficient as the two genes together, in
supporting B lymphocyte development.
We showed earlier that the expression pattern at the RNA
level of the two Vpre-B genes (and λ5) is similar in fetal liver
cells and in pro-B/pre-BI and large pre-BII bone marrow cells.
Single-cell RT-PCR of the latter two populations detected
Vpre-B1 (and λ5) mRNA in all cells, but Vpre-B2 transcripts were
found in only a portion (30%) of the same cells (6). This
discrepancy was proposed to be due to a difference in
sensitivity of the primer pairs used in the assays, a hypothesis
which is supported by our results herein: the number of large
pre-BII cells in Vpre-B1–/– mice is too high to be derived from
only one-third of the normal numbers of pre-BI cells. In
transfection experiments, both Vpre-B gene products have
been shown to assemble with the λ5 protein. However, it is
not known if they do so in vivo since there is no antibody
described that distinguishes the two Vpre-B proteins (6,20).
Our results here demonstrate that the Vpre-B2 gene product
can be incorporated in both the pro-B and pre-B cell receptors
of pro-B/pre-BI and large pre-BII bone marrow cells. Further-
more, Vpre-B2 can function in all steps of development, especi-
ally in the pre-BCR-dependent proliferative expansion of large
pre-BII cells. If the pre-BCR is also involved in allelic exclusion
of the IgH chain gene expression, then Vpre-B2 in pre-BCR
can also do that.
The importance of the membrane form of the µH chain and
the λ5 gene product at the pre-BCR stage was demonstrated
earlier in mice lacking the respective gene product (11,12).
Here we show that also the Vpre-B1 gene product is important
at the pre-BCR stage since the lack of Vpre-B1 causes an
enrichment of cells at the pre-BI stage, i.e. a partial block at
the transition into the pre-BCR stage. It has recently been
shown that not all Ig µH chains made from productively VDJH-
rearranged IgH loci can pair with the SL chain (21). Cells
expressing such non-pairing µH chains cannot form a pre-
BCR and do not participate in the proliferative expansion of
large pre-BII cells. Hence, cells expressing these µH chains
do not appear in the subsequent pre-B and B cell repertoires.
Some of the inability to pair may well be due to a structural
incompatibility of a VH domain in interactions with Vpre-B. If
so, then pairing to Vpre-B1 and Vpre-B2 may differ since some
of the nucleotide differences between the two Vpre-B genes
encode amino acid replacements. The VH repertoires of
normal and Vpre-B1–/– mice may, therefore, differ. This will be
investigated in future experiments.
The cells that progress through the pre-BCR stage in
Vpre-B1–/– mice seem to be normal in that they are expanded
by proliferation, and the number of more mature cells is just
slightly decreased as compared to heterozygous mutant and
wild-type mice. This did not significantly affect the number of
B cells detected in the periphery. This is in agreement
with experiments that showed that a minor decrease in the
production of pre-B cells (here pre-BII) in the marrow did not
affect the number of B cells in the periphery, while a major
decrease in pre-B cells did (22). Such a minor decrease in pre-
B cells could be envisioned as the situation in Vpre-B1-deficient
mice while a major (20 to 40-fold) reduction in pre-B(II) cells
is compatible with that found in mice lacking λ5 that also
have a significant decrease in the number of peripheral B cells.
Our data herein shows that mice expressing only one Vpre-B
gene (Vpre-B2) are immunocompetent and give rise to both
hapten- and carrier-specific antibodies when challenged with
T cell-dependent antigens. Thus, in mice, as is the case in
humans, one Vpre-B gene is sufficient, if not as efficient.
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